IRulya Therapeutics Inc. (NASDAQ:IRLA)
| Market Cap | $40.17M-88.5% |
| Revenue (ttm) | $0 |
| Net Income | -$92.48M-88.6% |
| EPS | -$68.91+68.4% |
| Shares Out | 1.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 61,276.491 |
| Open | $37.98 |
| Previous Close | $38.33 |
| Day's Range | $35.00 - $41.72 |
| 52-Week Range | $15.10 - $910.00 |
| Beta | 1.33 |
| Analysts | Buy |
| Price Target | $70.00(+77.22%) |
| Earnings Date | n/a |
About IRLA
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating IRLA in the last 3 months, one vote each. Issuer-paid research is not counted.
$IRLA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IRLA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IRLA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IRLA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IRLA Revenue by Segment
| Stock-based compensation | $12.09M | 48.65% |
| Consulting and professional costs | $4.98M | 20.04% |
| Fair value adjustment for warrants | $4.51M | 18.13% |
| Personnel | $2.10M | 8.47% |
| Clinical and contract manufacturing | $1.17M | 4.72% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IRLA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IRLA from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from IRLA’s recent data — informational, not investment advice